litlas
Log inCreate account

Boris Hadaschik

Active 2008–2025

171
Papers
20,424
Citations
68
h-index
151
i10-index

Citations

Citations per year for Boris Hadaschik1961: 2 citations1984: 3 citations1998: 2 citations2004: 1 citations2009: 1 citations2010: 12 citations2011: 8 citations2012: 21 citations2013: 46 citations2014: 92 citations2015: 159 citations2016: 258 citations2017: 224 citations2018: 308 citations2019: 965 citations2020: 900 citations2021: 1,035 citations2022: 737 citations2023: 563 citations2024: 1,072 citations2025: 503 citations2026: 22 citations1962–1983: no citations, so these years are not shown1985–1997: no citations, so these years are not shown1999–2003: no citations, so these years are not shown2005–2008: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,677 citing papers, 19.2% of this breakdownGermany: 996 citing papers, 11.4% of this breakdownChina: 633 citing papers, 7.2% of this breakdownItaly: 610 citing papers, 7% of this breakdownUnited Kingdom: 608 citing papers, 6.9% of this breakdownNetherlands: 385 citing papers, 4.4% of this breakdownCanada: 383 citing papers, 4.4% of this breakdownFrance: 324 citing papers, 3.7% of this breakdownSwitzerland: 306 citing papers, 3.5% of this breakdownAustralia: 298 citing papers, 3.4% of this breakdownBelgium: 218 citing papers, 2.5% of this breakdownJapan: 183 citing papers, 2.1% of this breakdown
0%19.2%Other 24.3%

Institutions

Fields

  • Medicine86.5%
  • Biochemistry, Genetics and Molecular Biology5%
  • Immunology and Microbiology2.5%
  • Computer Science2.1%
  • Engineering1.5%
  • Materials Science0.7%
  • Other1.7%

Topics

  • Prostate Cancer Treatment and Research20.9%
  • Prostate Cancer Diagnosis and Treatment18.4%
  • Radiopharmaceutical Chemistry and Applications8.7%
  • Urologic and reproductive health conditions2.8%
  • MRI in cancer diagnosis2.5%
  • Radiomics and Machine Learning in Medical Imaging2.5%
  • Other44.2%

Coauthors

All papers

Open in search
  1. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis

    Authors: Veeru Kasivisvanathan, Antti Rannikko, Marcelo Borghi, Valeria Panebianco, Lance A. Mynderse, Markku H. Vaarala, Alberto Briganti, Lars Budäus, Giles Hellawell, Richard Hindley, Monique J. Roobol, Scott E. Eggener, Maneesh Ghei, Arnauld Villers, Franck Bladou, Geert Villeirs, Jaspal Virdi, Silvan Boxler, G. Robert, Paras B. Singh, Wulphert Venderink, Boris Hadaschik, A. Ruffion, Jim C. Hu, Daniel Margolis, Sébastien Crouzet, Laurence Klotz, Samir S. Taneja, Peter A. Pinto, Inderbir S. Gill, Clare Allen, Francesco Giganti, Alex Freeman, Stephen Morris, Shonit Punwani, Norman Williams, Chris Brew‐Graves, Jonathan J Deeks, Yemisi Takwoingi, Mark Emberton, Caroline M. Moore - New England Journal of Medicine 2018 cited by 3,016

  2. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

    Authors: Matthew R. Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris Hadaschik, Julie N. Graff, David Olmos, Paul N. Mainwaring, Ji Youl Lee, Hiroji Uemura, Angela Lopez‐Gitlitz, Géralyn C. Trudel, Byron M. Espina, Youyi Shu, Youn C. Park, Wayne Rackoff, Margaret K. Yu, Eric J. Small - New England Journal of Medicine 2018 cited by 1,326

  3. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)

    Authors: Robert Seifert, Louise Emmett, Steven P. Rowe, Ken Herrmann, Boris Hadaschik, Jérémie Calais, Frederik L. Giesel, Robert E. Reiter, Tobias Maurer, Matthias Heck, Andrei Gafita, Michael J. Morris, Stefano Fanti, Wolfgang Weber, Thomas A. Hope, Michael S. Hofman, Wolfgang P. Fendler, Matthias Eiber - European Urology 2023 cited by 276

  4. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT

    Authors: Matthias Eiber, Ken Herrmann, Jérémie Calais, Boris Hadaschik, Frederik L. Giesel, Markus Hartenbach, Thomas A. Hope, Robert E. Reiter, Tobias Maurer, Wolfgang Weber, Wolfgang P. Fendler - Journal of Nuclear Medicine 2017 cited by 611

  5. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study

    Authors: Andrei Gafita, Jérémie Calais, Tristan Grogan, Boris Hadaschik, Hui Wang, Manuel Weber, Shahneen Sandhu, Clemens Kratochwil, Rouzbeh Esfandiari, Robert Tauber, Anna Zeldin, Hendrik Rathke, Wesley R. Armstrong, Andrew Robertson, Pan Thin, Calogero D’Alessandria, Matthew B. Rettig, Ebrahim S. Delpassand, Uwe Haberkorn, David Elashoff, Ken Herrmann, Johannes Czernin, Michael S. Hofman, Wolfgang P. Fendler, Matthias Eiber - The Lancet Oncology 2021 cited by 246

  6. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients

    Authors: Frederik L. Giesel, Boris Hadaschik, Jens Cardinale, Jan Philipp Radtke, Maria Vinsensia, Wencke Lehnert, Claudia Kesch, Yanis Tolstov, Samuel Singer, Niels Grabe, Stefan Duensing, Martin Schäfer, Oliver Neels, Walter Mier, Uwe Haberkorn, Klaus Kopka, Clemens Kratochwil - European Journal of Nuclear Medicine and Molecular Imaging 2016 cited by 602

  7. Apalutamide and Overall Survival in Prostate Cancer

    Authors: Matthew R. Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris Hadaschik, Julie N. Graff, David Olmos, Paul N. Mainwaring, Ji Youl Lee, Hiroji Uemura, Peter De Porre, Alexis K. Smith, Sabine Brookman‐May, Susan Li, Ke Zhang, Brendan Rooney, Angela Lopez‐Gitlitz, Eric J. Small - European Urology 2020 cited by 290

  8. Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches

    Authors: Philip Posdzich, Christopher Darr, Thomas Hilser, Milan Wahl, Ken Herrmann, Boris Hadaschik, Viktor Grünwald - Cancers 2023 cited by 129

  9. Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer

    Authors: Andrei Gafita, Loïc Djaileb, Isabel Rauscher, Wolfgang P. Fendler, Boris Hadaschik, Steven P. Rowe, Ken Herrmann, Jérémie Calais, Matthew B. Rettig, Matthias Eiber, Manuel Weber, Matthias Benz, Andrea Farolfi - Radiology 2023 cited by 101

  10. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

    Authors: Arlene O. Siefker‐Radtke, Andrea Necchi, Se Hoon Park, Jesús García-Donás, Robert Huddart, Earle F. Burgess, Mark T. Fleming, Arash Rezazadeh Kalebasty, Begoña Mellado, Sergei Varlamov, Monika Joshi, Ignacio Durán, Scott T. Tagawa, Yousef Zakharia, Sydney Akapame, Ademi Santiago-Walker, Manish Monga, Anne O’Hagan, Yohann Loriot, Andrea Necchi, Yohann Loriot, Se Hoon Park, Scott T. Tagawa, Aude Fléchon, B. Ya. Alexeev, Sergey Varlamov, Robert Huddart, Earle F. Burgess, Arash Rezazadeh, Arlene O. Siefker‐Radtke, Yann Vano, Donatello Gasparro, Alketa Hamzaj, Eugeniy Kopyltsov, Jesus Gracia Donas, Begoña Mellado, Omi Parikh, Peter Schatteman, Stéphane Culine, Nadine Houédé, Sylvie Zanetta, Gaetano Facchini, Giorgio V. Scagliotti, Giovanni Schinzari, Jae‐Lyun Lee, Mikhail Shkolnik, Mark T. Fleming, Monika Joshi, Peter H. O’Donnell, Herbert Stöger, Karel Decaestecker, Luc Dirix, Jean Pascal Machiels, Dephine Borchiellini, R. Delva, Frédéric Rolland, Boris Hadaschik, Margitta Retz, Eli Rosenbaum, Umberto Basso, Alessandra Mosca, Hyo Jin Lee, Dong Bok Shin, C. Cebotaru, Ignacio Durán, Víctor Moreno, José Luis Perez‐Gracia, Álvaro Pinto, Wen-Pin Su, Shian‐Shiang Wang, John D. Hainsworth, Ian D. Schnadig, Sandhya Srinivas, Nicholas J. Vogelzang, Wolfgang Loidl, Johannes Meran, M. Gross Goupil, Florence Joly, Florian Imkamp, Theodor Klotz, S. Krege, Matthias May, Wolfgang Schultze-Seemann, Arne Strauß, Uwe Zimmermann, Daniel Keizman, Avivit Peer, Avishai Sella, Rossana Berardi, Ugo De Giorgi, Cora N. Sternberg, Sun Young Rha, Iurie Bulat, А. А. Измайлов, Vsevolod Matveev, Vladimir Vladimirov, Joan Carles, Albert Font, M.I. Sáez, Isabel Syndikus and 6 more - The Lancet Oncology 2022 cited by 169

  11. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer

    Authors: Stefano Fanti, Karolien Goffin, Boris Hadaschik, Ken Herrmann, Tobias Maurer, Steven MacLennan, Daniela E. Oprea‐Lager, Wim J.G. Oyen, Olivier Rouvière, Nicolas Mottet, Anders Bjartell - European Journal of Nuclear Medicine and Molecular Imaging 2020 cited by 205

  12. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer

    Authors: Wolfgang P. Fendler, Manuel Weber, Amir Iravani, Michael S. Hofman, Jérémie Calais, Johannes Czernin, Harun Ilhan, Fred Saad, Eric J. Small, Matthew R. Smith, Paola M. Perez, Thomas A. Hope, Isabel Rauscher, Anil Londhe, Angela Lopez‐Gitlitz, Shinta Cheng, Tobias Maurer, Ken Herrmann, Matthias Eiber, Boris Hadaschik - Clinical Cancer Research 2019 cited by 267

  13. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis

    Authors: Robert Seifert, Katharina Kessel, Katrin Schlack, Manuel Weber, Ken Herrmann, Maximilian Spanke, Wolfgang P. Fendler, Boris Hadaschik, Jens Kleesiek, Michael Schäfers, Matthias Weckesser, Martin Boegemann, Kambiz Rahbar - European Journal of Nuclear Medicine and Molecular Imaging 2020 cited by 152

  14. Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria

    Authors: Stefano Fanti, Boris Hadaschik, Ken Herrmann - Journal of Nuclear Medicine 2019 cited by 157

  15. Next generation radiotheranostics promoting precision medicine

    Authors: Kelsey L. Pomykala, Boris Hadaschik, Oliver Sartor, Silke Gillessen, Christopher J. Sweeney, Tim Maughan, Michael S. Hofman, Ken Herrmann - Annals of Oncology 2023 cited by 69

  16. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions

    Authors: Ali Afshar‐Oromieh, A. Malcher, Matthias Eder, Michael Eisenhut, Heinz Linhart, Boris Hadaschik, Tim Holland‐Letz, Frederik L. Giesel, Clemens Kratochwil, Sabine Haufe, Uwe Haberkorn, Christian M. Zechmann - European Journal of Nuclear Medicine and Molecular Imaging 2012 cited by 924

  17. Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets

    Authors: Stephan Lang, Kirsten Bruderek, Cordelia Kaspar, Benedikt Höing, Oliver Kanaan, Nina Dominas, Timon Hussain, Freya Droege, Christian Eyth, Boris Hadaschik, Sven Brandau - Clinical Cancer Research 2018 cited by 211

  18. Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities

    Authors: Nader Hirmas, Rainer Hamacher, Miriam Sraieb, Marc Ingenwerth, Lukas Kessler, Kim M. Pabst, Francesco Barbato, Katharina Lueckerath, Stefan Kasper, Michael Nader, Hans‐Ulrich Schildhaus, Claudia Kesch, Bastian von Tresckow, Christine Hanoun, Hubertus Hautzel, Clemens Aigner, Martin Glas, Martin Stuschke, Sherko Kümmel, Philipp Harter, Céline Lugnier, Waldemar Uhl, Marco Niedergethmann, Boris Hadaschik, Viktor Grünwald, Jens T. Siveke, Ken Herrmann, Wolfgang P. Fendler - Journal of Nuclear Medicine 2022 cited by 70

  19. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

    Authors: Ali Afshar‐Oromieh, Eleni Avtzi, Frederik L. Giesel, Tim Holland‐Letz, Heinz Linhart, Matthias Eder, Michael Eisenhut, Silvan Boxler, Boris Hadaschik, Clemens Kratochwil, Wilko Weichert, Klaus Kopka, Jürgen Debus, Uwe Haberkorn - European Journal of Nuclear Medicine and Molecular Imaging 2014 cited by 974

  20. Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort

    Authors: Stefanie Zschäbitz, Nadine Biernath, Thomas Hilser, Alexander Höllein, Friedemann Zengerling, Jozefina Cascucelli, Pia Paffenholz, Daniel Seidl, Christoph Lutz, Katrin Schlack, D. Kingreen, Niklas Klümper, Philipp Ivanyi, Gunhild von Amsberg, Hendrik Heers, Florian Roghmann, Robert L. Tauber, Richard Cathomas, Luisa Hofer, Günter Niegisch, M. Klee, Roland Ehrenberg, Andreas Hassler, Boris Hadaschik, Viktor Grünwald, Christopher Darr - European Urology Open Science 2023 cited by 45

  21. The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction

    Authors: Florian Distler, Jan Philipp Radtke, David Bonekamp, Claudia Kesch, Heinz-Peter Schlemmer, Kathrin Wieczorek, Marietta Kirchner, Sascha Pahernik, Markus Hohenfellner, Boris Hadaschik - The Journal of Urology 2017 cited by 245

  22. Unspecific18F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer

    Authors: Robert Seifert, Tuğçe Telli, Marcel Opitz, Francesco Barbato, Christoph Berliner, Michael Nader, Lale Umutlu, Martin Stuschke, Boris Hadaschik, Ken Herrmann, Wolfgang P. Fendler - Journal of Nuclear Medicine 2022 cited by 70

  23. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer

    Authors: Ali Afshar‐Oromieh, Christian M. Zechmann, A. Malcher, Matthias Eder, Michael Eisenhut, Heinz Linhart, Tim Holland‐Letz, Boris Hadaschik, Frederik L. Giesel, Jürgen Debus, Uwe Haberkorn - European Journal of Nuclear Medicine and Molecular Imaging 2013 cited by 928

  24. Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17

    Authors: Richard Cathomas, Sacha I. Rothschild, Stefanie Hayoz, Lukas Bubendorf, Berna C. Özdemir, Bernhard Kiss, Andreas Erdmann, Stefanie Aeppli, Nicolas Mach, Räto T. Strebel, Boris Hadaschik, Dominik Berthold, Hubert John, Deborah Zihler, Mathias Schmid, Ilaria Alborelli, Martina Schneider, Jana Musilová, Martin Spahn, Ulf Petrausch - Journal of Clinical Oncology 2023 cited by 42